Literature DB >> 23475013

Diagnosing autism in a clinical sample of adults with intellectual disabilities: how useful are the ADOS and the ADI-R?

Tanja Sappok1, Albert Diefenbacher, Jan Budczies, Christoph Schade, Claudia Grubich, Thomas Bergmann, Sven Bölte, Isabel Dziobek.   

Abstract

Intellectual disability (ID) and autism spectrum disorder (ASD) are frequently co-occurring conditions. Carefully diagnosing ASD in individuals with ID would allow for more tailored clinical interventions that would improve mental health and quality of life. In this study, we evaluated the psychometric properties of the Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R) in a clinical sample of 79 adults with ID who were suspected of also having ASD. In the testable cases (68%), the ADOS was over-inclusive (specificity 45%) but highly sensitive (100%) of ASD. In the ADI-R, the feasibility was 37%, with a sensitivity of 88% and a specificity of 80%. Previously proposed adaptations of the ADOS algorithm were evaluated, and new items and tasks were suggested. The ADOS and the ADI-R were found to be valuable diagnostic tools for adults with ID. Adjustments of the setting and the tasks may further improve their feasibility and specificity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23475013     DOI: 10.1016/j.ridd.2013.01.028

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  18 in total

1.  Comorbid intellectual disability.

Authors:  Tanja Sappok; Albert Diefenbacher; Thomas Bergmann
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

2.  Diagnosing ASD in Adults Without ID: Accuracy of the ADOS-2 and the ADI-R.

Authors:  Laura Fusar-Poli; Natascia Brondino; Matteo Rocchetti; Cristina Panisi; Umberto Provenzani; Stefano Damiani; Pierluigi Politi
Journal:  J Autism Dev Disord       Date:  2017-11

3.  Brief Report: Factors Influencing Healthcare Satisfaction in Adults with Autism Spectrum Disorder.

Authors:  Alan H Gerber; Carolyn E B McCormick; Todd P Levine; Eric M Morrow; Thomas F Anders; Stephen J Sheinkopf
Journal:  J Autism Dev Disord       Date:  2017-06

4.  The missing link: delayed emotional development predicts challenging behavior in adults with intellectual disability.

Authors:  Tanja Sappok; Jan Budczies; Isabel Dziobek; Sven Bölte; Anton Dosen; Albert Diefenbacher
Journal:  J Autism Dev Disord       Date:  2014-04

5.  Rates and Predictors of Co-occurring Autism Spectrum Disorder in Boys with Fragile X Syndrome.

Authors:  Eileen Haebig; Audra Sterling; Andrea Barton-Hulsey; Laura Friedman
Journal:  Autism Dev Lang Impair       Date:  2020-02-12

6.  Clinical Validity of the ADI-R in a US-Based Latino Population.

Authors:  Sandra B Vanegas; Sandra Magaña; Miguel Morales; Ellyn McNamara
Journal:  J Autism Dev Disord       Date:  2016-05

Review 7.  Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome.

Authors:  Latha Soorya; Jill Leon; M Pilar Trelles; Audrey Thurm
Journal:  Clin Neuropsychol       Date:  2017-12-21       Impact factor: 3.535

8.  Diagnosing Autism in Adults with Intellectual Disability: Validation of the DiBAS-R in an Independent Sample.

Authors:  Manuel Heinrich; Julia Böhm; Tanja Sappok
Journal:  J Autism Dev Disord       Date:  2018-02

9.  The autism spectrum phenotype in ADNP syndrome.

Authors:  Anne B Arnett; Candace L Rhoads; Kendra Hoekzema; Tychele N Turner; Jennifer Gerdts; Arianne S Wallace; Sandra Bedrosian-Sermone; Evan E Eichler; Raphael A Bernier
Journal:  Autism Res       Date:  2018-08-14       Impact factor: 5.216

10.  Characterisation of the clinical phenotype in Phelan-McDermid syndrome.

Authors:  Mónica Burdeus-Olavarrieta; Antonia San José-Cáceres; Alicia García-Alcón; Javier González-Peñas; Patricia Hernández-Jusdado; Mara Parellada-Redondo
Journal:  J Neurodev Disord       Date:  2021-07-10       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.